Nurses to vote on pay deal as potential strike looms
Almost 350,000 nursing staff in England, Wales and Northern Ireland will be asked to vote from Monday on a 3.6% pay increase.
The Royal College of Nursing (RCN) has already dismissed the award as "grotesque" and says the vote will be crucial in determining the next steps which could include a ballot for strike action.
A bitter pay dispute saw nurses striking in England, Wales and Northern Ireland from late 2022 and through the winter. Some members of other health unions also staged walkouts over pay.
With the possibility of another round of industrial action looming, the vote is being billed as the biggest single vote by the profession ever launched in the UK.
Ministers in England, Wales and Northern Ireland all announced pay awards following review body recommendations.
There was a 5.4% average increase for resident doctors, formally known as junior doctors, 4% for consultants and other senior doctors, and 3.6% for nurses and other health workers.
RCN General Secretary Professor Nicola Ranger said that the government had "once again put nursing at the back of the queue when it comes to pay".
"Nursing is an incredible career, but despite being the most valued profession by the public we continue to be weighted to the bottom of the NHS pay scale and are set to receive one of the lowest pay awards."
According to the Ranger, nursing staff in England have endured "over a decade of pay erosion", which has resulted in "skyrocketing" numbers of nurses quitting.
"It is time to show that nurses are valued and, from today, hundreds of thousands of nursing staff working in the NHS will give their verdict on whether 3.6% is enough," Ranger will say.
Resident doctors in England are already being balloted on strike action over pay. Other health unions are organising votes on the pay awards.
All this may cast a shadow over a government 10-year plan for the NHS in England due in the next few weeks.
The Scottish government has already agreed a two-year 8% pay offer with health unions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
18 minutes ago
- Medscape
Add-On Niraparib May Slow mHSPC
Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) genetic alterations, according to findings from the AMPLITUDE trial. An interim analysis also demonstrated an early trend toward improved overall survival in patients who received niraparib. These findings support adding niraparib to abiraterone acetate plus prednisone 'as a new treatment option' in patients with HRR alterations, said Study Chief Gerhardt Attard, MD, PhD, chair of medical oncology, University College London Cancer Institute, London, England, speaking at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. The findings also highlight that 'it's going to be incredibly important that patients who get diagnosed with hormone-sensitive prostate cancer are tested to see if they have these mutations, so they can be offered the right therapy at the right time,' Outside Expert Bradley McGregor, MD, with Dana-Farber Cancer Institute in Boston, said during a press briefing. Ultimately, 'you don't know if you don't test,' McGregor added. About one quarter of patients with metastatic castration-sensitive prostate cancer have alterations in HRR genes, about half of which are BRCA mutations. These patients typically experience faster disease progression and worse outcomes. An androgen receptor pathway inhibitor, such as abiraterone, alongside androgen deprivation therapy with or without docetaxel, is standard therapy for these patients, but 'there is still a need for treatments that are tailored to patients whose tumors harbor HRR alterations,' Attard said in a press release. Adding niraparib to this standard regimen could help improve survival in these patients. In 2023, the FDA approved niraparib and abiraterone acetate to treat BRCA -mutated metastatic castration-resistant prostate cancer, after findings from the MAGNITUDE study demonstrated improved progression-free survival (PFS). The phase 3 AMPLITUDE trial set out to evaluate whether this combination would yield similar survival benefits in metastatic castration-sensitive prostate cancer with HRR mutations. In the study, 696 patients (median age, 68 years) with metastatic castration-sensitive prostate cancer and one or more HRR gene alterations were randomly allocated (1:1) to niraparib with abiraterone acetate plus prednisone or placebo with abiraterone acetate plus prednisone. Exclusion criteria included any prior PARP inhibitor therapy or androgen receptor pathway inhibitor other than abiraterone. Eligible patients could have received at most 6 months of androgen deprivation therapy, ≤ 6 cycles of docetaxel, ≤ 45 days of abiraterone acetate plus prednisone and palliative radiation. Baseline characteristics were well balanced between the groups. Just over half the patients in each group had BRCA1 or BRCA2 alterations. The majority had an electrocorticogram performance status of 0, but high-risk features with a predominance for synchronous metastatic disease and metastatic high volume. About 16% had received prior docetaxel, in keeping with real world data, Attard noted. At a median follow-up of 30.8 months, niraparib plus standard therapy led to a significant 37% reduction in the risk for radiographic progression or death. The median radiographic PFS (rPFS) was not reached in the niraparib group vs 29.5 months in the placebo group (hazard ratio [HR], 0.63; P = .0001). Patients with BRCA alterations, in particular, showed the greatest benefit, with niraparib reducing the risk for radiographic progression or death by 48% compared to placebo (median rPFS not reached vs 26 months; HR, 0.52; P < .0001). On the key secondary endpoint of time to symptomatic progression, adding niraparib led to a 'statistically and clinically' significant benefit — a 50% lower in the risk for symptomatic progression in the full population (HR, 0.50), and a 56% lower risk in BRCA -mutant group (HR, 0.44). The first interim analysis also showed an early trend toward improved overall survival favoring the niraparib combination, with a reduction in the risk for death of 21% in the HRR-mutant population (HR, 0.79; P = .10) and 25% (HR, 0.75; P = .15) in the BRCA -mutant population. Grade 3/4 adverse events were more common with the niraparib combination group compared to the placebo group (75% vs 59%), with anemia and hypertension being the most common. However, treatment discontinuations due to adverse remained low (15% with niraparib vs 10% with placebo). Attard noted, however, that half the target number of patients required for the final analysis died. Still, 'in my view, there's a clear trend for favoring survival in the patients randomized to niraparib,' he told attendees. 'Exciting News' for Patients The AMPLITUDE results are 'really exciting news for our patients,' McGregor said. Considering the poor prognosis of patients with metastatic castration-sensitive prostate cancer, 'it is reasonable to prioritize early access to PARP inhibitors for these men, at least for the ones with BRCA mutations,' added ASCO discussant Joaquin Mateo, MD, PhD, with Vall d'Hebron Institute of Oncology, Barcelona, Spain. However, Mateo explained, 'I think that for patients with mutations in the other genes, I will be more prudent, and I'll be on the lookout for the overall survival data to mature.' The other key conclusion, Mateo said, is that genomic profiling 'should be moved earlier into the patient course, and I am confident that embedding genomic profiling into the diagnostic evaluations of metastatic prostate cancer is also going to result in better quality of testing, more efficacious testing, and also a more equitable framework of access to testing for patients.'
Yahoo
24 minutes ago
- Yahoo
Healthcare firm Totally collapses but divisions sold
Former NHS 111 urgent care provider Totally has collapsed into administration, but said a deal to sell its main divisions will see the 'uninterrupted provision' of all its services. The Derby-based healthcare firm – which lost the NHS 111 support contract in February this year – has appointed Ernst & Young partners Tim Vance and Sam Woodward as joint administrators after failing to secure bids or strategic investors for the entire firm. It said that following the appointment, the sale of its selective care and corporate wellbeing subsidiaries, as well as the urgent care division, was completed to rival PHL Group. 'This transaction sees the continued and uninterrupted provision of all services previously delivered by the group,' Totally said. Totally employed more than 1,400 employees, according to its 2023-2024 annual report. The group added: 'PHL Group will make separate announcements shortly, including communication with the customers, suppliers and employees of the elective care and urgent care divisions, and the corporate wellbeing business, which are all continuing to provide all services as normal following the transaction.' The company's failure comes after a difficult past year, with the firm losing the NHS 111 contract worth £13 million and then revealing last month it was facing a potential medical negligence claim related to an incident in January 2018. At the time, it warned the size of the liability for the claim could be more than the £10 million claim limit on its insurance policy. It launched a strategic review to look at options, including the sale of subsidiaries 'receiving strategic investment or undertaking some other form of comparable corporate action'. Shares in the firm plummeted at the time. On June 6, it announced its intention to appoint administrators after the review had failed to see any 'solvent' offers for parent firm Totally and suspended its shares from trading on London's junior Aim market. PHL – the buyer of its trading divisions – was launched in 2009 and runs services in the UK and overseas, including integrated urgent care, urgent treatment centres, surgical insourcing, custody healthcare, ADHD services and general practice. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
NHS issues urgent warning for a million blood donors amid 'challenging' shortage
A "challenging" blood shortage is facing the NHS as officials say it needs one million regular donors to maintain its supply. The NHS Blood and Transplant (NHSBT) has said that more must be done to avoid a 'red alert', which means that blood supply is so low that there is a threat to public safety. Officials described the last year as 'challenging' for blood stocks, highlighting how just two per cent of the population keep the nation's blood stocks afloat. It meant that officials issued an 'amber alert' over supply for hospitals. This means just under 800,000 people sustained the whole of England's blood supply over the past 12 months and NHSBT said one million donors are needed to meet demand. NHSBT said that there has been a rise in the number of people who registered to be donors in the last year, but only 24 per cent of these have gone on to donate. The amber alert was triggered in July 2024 after a cyber attack on London hospitals. And blood stocks have remained low ever since, officials said. It said there is a "critical" need for more donors who have the so-called universal blood type – O negative blood – which is needed for treatment in emergencies. There is also a need for more black donors, who are more likely to have specific blood types which can help treat people with sickle cell disease. NHSBT chief executive Dr Jo Farrar, said: "There are many thousands of people who donate regularly and help us keep patients alive. Thank you. You are amazing. You keep the NHS going and save and transform thousands of lives a year. 'Our stocks over the past 12 months have been challenging. If we had a million regular donors, this would help keep our stocks healthy – you'd truly be one in a million. 'Please book an appointment today, experience how good it feels to save lives, and come and do it again in a few months.' Two thirds of the blood collected is used to treat people who rely on blood transfusions including people with cancer and those with blood conditions. Health Minister Baroness Merron, said: "The NHS is in urgent need of more lifesaving blood donors from all backgrounds. "We are working alongside NHS Blood and Transplant to make donating blood easier than ever before, opening up new donor centres and making appointments available closer to home." Recommended reading: 5 drinks that could help hay fever symptoms amid pollen bomb Global life expectancy could rise by almost 5 years by 2050 What medical conditions qualify for a Blue Badge? See who is eligible To donate blood, you'll need to book an appointment online or through the NHS Give Blood app, or by calling 0300 123 23 23. The process involves a health screening, a brief donation period, and a post-donation rest with a free drink and snack. The entire appointment takes about an hour.
